Skip to main content
SymBio Pharmaceuticals Limited logo

SymBio Pharmaceuticals Limited — Investor Relations & Filings

Ticker · 4582 ISIN · JP3383050006 T Manufacturing
Open in API
Filings indexed 88 across all filing types
Latest filing 2026-06-09 Regulatory Filings
Country JP Japan
Listing T 4582

About SymBio Pharmaceuticals Limited

https://www.symbiopharma.com/en/

SymBio Pharmaceuticals Limited is a specialty pharmaceutical company focused on the development and commercialization of new drug candidates. The company's business model involves acquiring development and marketing rights for promising pharmaceuticals from other bio-ventures and pharmaceutical firms to address unmet medical needs. Its core therapeutic areas include oncology, hematology, and rare diseases. A key product in its portfolio is bendamustine hydrochloride (Treakisym), an agent used in the treatment of hematologic cancers such as low-grade non-Hodgkin's lymphoma and chronic lymphocytic leukemia. SymBio aims to deliver innovative treatments to patients by advancing its pipeline of specialized drugs.

Recent filings

Filing Released Lang Actions
進行性多巣性白質脳症を対象とした、NIH主導による IV BCVの臨床試験で、患者登録（FPI）を完了
Regulatory Filings Classification · 75% confidence The document is a corporate press release announcing completion of first patient enrollment in an NIH-led clinical trial of IV BCV for PML. It does not contain financial results, governance matter, dividends, share issues, or meeting materials, nor is it a full financial report. It is a general operational/regulatory announcement, so it falls under the fallback category Regulatory Filings (RNS).
2026-06-09 Japanese
第三者割当により発行された第58回新株予約権及び第66回新株予約権（行使価額修正条項付）の 月間行使状況に関するお知らせ
Share Issue/Capital Change Classification · 85% confidence The document is a notice of the monthly exercise status of third-party allotted share subscription rights (warrants), detailing share issuance numbers and exercise ratios. This is an announcement of new share issuance/capital change rather than a full financial report, management change, or repurchase. It best fits the “Share Issue/Capital Change” category (SHA).
2026-06-01 Japanese
超高感度（ピコレベル）イムノクロマトシステム 商業化に向け、安定供給体制を確立
Regulatory Filings Classification · 85% confidence The document is a corporate press release announcing a supply contract with two partners for the commercialization of a high-sensitivity immunochromatography system. It contains no financial statements, vote results, share transactions, or regulatory certifications; it is not an AGM, earnings release, or formal financial report. This type of business update falls under general regulatory or compliance announcements that do not fit other specific categories. Therefore, it should be classified as a Regulatory Filing (RNS).
2026-05-18 Japanese
2026年12月期 第１四半期決算短信〔日本基準〕(連結)
Regulatory Filings
2026-05-07 Japanese
第三者割当により発行された第58回新株予約権及び第66回新株予約権（行使価額修正条項付）の 月間行使状況に関するお知らせ
Regulatory Filings
2026-05-01 Japanese
第三者割当により発行された第66回新株予約権（行使価額修正条項付）の大量行使に関するお知らせ
Regulatory Filings
2026-04-21 Japanese

Browse filings by year

12 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.